Analyst Conference Summaries

Biotechnology Investor Aids

Arrowhead Pharmaceuticals
ARWR

conference date: August 5, 2021 @ 1:30 PM Pacific Time

Arrowhead Pharmaceuticals Is A Smart Long-Term Opportunity [September 11, 2020 at Seeking Alpha]

Arrowhead Pharmaceuticals RNA Therapy Pipeline Is Promising [July 19, 2019 at Seeking Alpha]

2021
Arrowhead
Pharmaceuticals
fiscal Q2 2021
Arrowhead
Pharmaceuticals
fiscal Q3 2021
   
May 4, 2021 Aug. 5, 2021    
2020
Arrowhead
Pharmaceuticals
fiscal Q2 2020
Arrowhead
Pharmaceuticals
fiscal Q3 2020
Arrowhead
Pharmaceuticals
fiscal Q4 2020
Arrowhead
Pharmaceuticals
fiscal Q1 2021
May 7, 2020 Aug. 5, 2020 Nov. 23, 2020 Feb. 4, 2021
2019
  Arrowhead
Pharmaceuticals
fiscal Q3 2019
Arrowhead
Pharmaceuticals
fiscal Q4 2019
Arrowhead
Pharmaceuticals
fiscal Q1 2020
na August 5, 2019 Nov. 25, 2019 Feb. 5, 2020

Arrowhead Pharmaceuticals (ARWR) is a clinical-stage biotechnology company specializing in RNAi therapies for genetic diseases.

Arrowhead Pharmaceutical web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 BIIB
 BMY
 CLDX
 CLSN
 DRNA
 EPZM
 GILD
 GLYC
 ILMN
 INO
 IONS
 ISRG
 MCHP
 MRNA
 PLX
 REGN
 RNA
 SGEN
 SYRS
 TTPH
 VBLT
 VSTM
 XLRN
       

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2021 William P. Meyers